Trends and Insights for Your Oncology Trial: Considerations for biotech companies
November 12, 2019
10:00AM - 11:00AM

Webinar Summary

A record number of new oncology drugs have been approved in recent years, bringing new treatment options to patients. However, despite robust levels of pipeline activity, oncology trials are complex and remain a challenging area for research and development.

Join this webinar to learn about trends shaping the development and delivery of cancer treatment worldwide. We will share insights and best practices to help ensure your future oncology trials are designed to be quick and efficient and yield high-quality data for the best chance of success. Our experts will address specific considerations for biotech companies embarking on oncology trials.

Key Learnings

  • Understand top trends driving change in oncology clinical development today and through 2023.
  • Recognize the impact of new therapies and care standards on trial planning and design.
  • Learn how to apply real world evidence to trial design, trial start-up, and trial conduct for more efficient and effective trials.

Murray Aitken

Executive Director, IQVIA Institute for Human Data Science

Murray Aitken is a senior vice president at IQVIA and the executive director of the IQVIA Institute for Human Data Science. Aitken is a renowned expert on critical healthcare issues around the world, including the role of medicine, the disruptive impact of technology and the use of data science in improving decision making and accelerating innovation.

Throughout his 17-year tenure at IQVIA (formerly IMS Health and QuintilesIMS), Aitken served in various roles responsible for healthcare insights, corporate strategy, and consulting and services. Prior, Aitken was a partner at McKinsey & Company in New Jersey and Los Angeles in the U.S. and in Seoul, South Korea, covering a broad range of industries, including life sciences and consumer goods.

He holds an MBA, with distinction, from Harvard University and a Masters of Commerce from the University of Auckland in New Zealand.

Andrew Zupnick, Ph.D.

Vice President, Oncology Strategy, IQVIA Biotech

Focused exclusively in oncology research for nearly 20 years, Dr. Andrew Zupnick leads the Oncology Strategy team at IQVIA Biotech. He and his team have the pleasure of reviewing more than 100 oncology protocols per year, where they work to provide strategic guidance and consultative support to align IQVIA Biotech and IQVIA’s oncology-specific solutions with the needs of our customers and projects. Additional roles at IQVIA Biotech include key account oversight, development of custom, protocol-centric solutions for new oncology projects, corporate initiatives, and training to internal staff on drug mechanisms and industry trends.

Dr. Zupnick holds a Ph.D. in biological sciences with a focus in oncology from Columbia University. He pursued his undergraduate research in biology and biomedical engineering at the Massachusetts Institute of Technology.

Contact Us
Contact Us
Contact Us

Email Us

Get in touch today to discover the right solutions for you.

Call Us

We are pleased to speak with you during our standard business hours.

U.S. Toll-Free only
+1 866 267 4479

For international call please find a number in our toll-free list.

Media Inquiries

Please use this form to reach out to our media team with inquiries. Thank you.